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Abstract
Palliative care is developing for people with neurological disease.  This may be integrated early in the dise-
ase progression, and may have a variable input over time. The careful assessment and management of all 
issues — physical, psychological, social and spiritual — provides the patient and family the opportunity to 
maximise quality of life. This requires a multidisciplinary approach and close collaboration with other services.
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Introduction
Palliative care is primarily associated with the care 
of patients with advanced cancer but there has been 
increasing pressure for services to be involved with 
patients with other progressive diseases. Neurological 
disease, including stroke, accounts for over 12% of all 
deaths worldwide and is thus an area for importance 
for palliative care [1].
The principles of palliative care should be the same 
for any disease process, although there are specific 
differences according to different diagnoses. In neu-
rological disease there is a wide variation in preva-
lence and prognosis — amyotrophic lateral sclerosis 
(ALS) has a prevalence of 7/100,000 and an average 
prognosis of two to three years; Parkinson’s disease 
(PD) has an overall prevalence of 180/100,00 but 
for people over 80 years the prevalence increases to 
1750/100,000, and the mean prognosis is 14 years but 
many people live 20 to 30 years; the dementias have 
prevalence of 700/100,000 and the mean prognosis is 
8 to 10 years but many may live longer. There is also 
great variability not only between disease groups but 
within disease progression — although the average 
prognosis of ALS is 2 to 3 years 25% are alive at 5 years 
and 10% at 10 years [2].
The role of palliative care
There is increasing awareness of the need for 
palliative care in neurology and in 2016 the Eu-
ropean Academy of Neurology (EAN) and the Eu-
ropean Association for Palliative Care (EAPC) produced 
a joint Consensus review on the care of people with 
chronic and progressive neurological disease [3]. This 
has suggested that “palliative care should be consi-
dered early in the disease progression, depending on 
the underlying prognosis”.  Moreover, it has suggested 
that there are several areas that should be addressed:
• Early integration  of palliative care;
• Multidisciplinary care approach;
• Communication, including advance care planning;
• Symptom management;
• Carer support;
• End of life care;
• Training and education of both neurologists in 
palliative care and palliative care specialists in 
neurology [3].
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Multidisciplinary team approach
The Consensus paper recommends a multidisci-
plinary approach to care, including at least three 
different professions — physician, nurse and social 
worker/counsellor/psychologist [3]. This team ap-
proach is very helpful in allowing each member to 
contribute their expertise and collaborate together. 
For neurological patients this may also include the 
physiotherapist, occupational therapist, dietitian and 
speech and language therapist.  There is the need to 
collaborate with other teams — for instance for a pa-
tient with ALS there may be the need to collaborate 
with gastroenterology if a gastrostomy is inserted or 
respiratory medicine if ventilatory support is needed. 
This can be a challenge, as teams may act in different 
ways, with a different ethos and working methods. It 
is important to ensure that there is close collaboration 
and understanding so that the patient and family 
receive a truly co-ordinated approach [11].
There is limited evidence of the effectiveness of 
multidisciplinary team approach.  However, in ALS 
there are now several studies suggesting that such 
an approach increases quality of life, helps to ma-
nage symptoms and may extend life — one study 
showing a survival for patients attending a specialised 
multidisciplinary ALS clinic having a mean survival of 
19 months, compared to 11 months for those atten-
ding a neurology clinic [12].
The care of a patient with neurological disease may 
be by many different teams — varying from country 
to country and area to area. There is an overlap in 
the care from rehabilitation, neurology and rehabi-
litation [13]. There may be specific areas that each 
team will be most involved with — for neurology 
the investigation and diagnosis, rehabilitation the 
physical management and cognitive/communication 
issues and palliative care in end of life care, spiritual 
support, coping with loss, but all should be managing 
symptoms and neurology and rehabilitation mana-
ging the disease and aiming to prevent long-term 
complications [130]. In some areas one team will be 
the primary multidisciplinary team, collaborating with 
other teams as necessary.
Communication
The diagnosis of a neurological illness is often 
a great shock to patients and families and their 
knowledge of the disease and the implications may 
be low, compared the diagnosis of cancer.  How the 
diagnosis is presented is crucial to the later care, and 
Thus the role of palliative care for neurological 
patients is becoming clearer and will continue to de-
velop. As defined by the World Health Organisation 
this will include the various aspects of care:
• Physical — symptoms, mobility issues, practical 
issues of disease progression;
• Psychological — the fears and concerns of patients 
about the disease, and often overshadowed by 
cognitive change or loss;
• Social — the issues for care givers and families, 
coping with progressive physical, and often co-
gnitive, loss;
• Spiritual — the deeper issues and fear of patients [4].
All these aspects need to be considered and ad-
dressed, with specific issues becoming more prono-
unced for some diseases — for instance in PD the 
mobility, communication and often cognitive changes 
may predominate, whereas in Huntington’s disease 
(HD) there are physical issues associated with chorea, 
but cognitive change and dementia become more 
pronounced as the disease progresses.
The effectiveness of palliative care  
in neurology
There has been increasing evidence of the effec-
tiveness for palliative care generally — with studies 
showing increased quality of life and survival with 
early palliative care in lung cancer [5] and increased 
deaths at home with specialist palliative home care [6]. 
The evidence for neurological palliative care is limited 
but increasing.
A study in London of a short term input palliative 
care for people with multiple sclerosis (MS) showed 
not only an improvement in symptoms in the group 
receiving palliative care, whereas there was deterio-
ration in the control group, but there was an impro-
vement of caregiver burden [7] and this care was also 
cost effective [8]. A similar study conducted in Turin 
with the involvement of the wider multidisciplinary 
palliative care team with a broader group of neuro-
logical diseases showed improvement in symptoms 
– pain, breathlessness, sleep disturbance and bowel 
symptoms — and quality of life, but no significant 
changes in caregiver burden [9]. A further study on 
short term input in MS showed that extra training in 
palliative care and support of specialist nurses showed 
reduced symptom burden but no effect on quality of 
life or other outcomes [10].
Thus there is some evidence that palliative care is 
helpful in the care of neurological patients but further 
research is needed.
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may influence the end of life phase. For instance if 
a person with ALS is told, or reads on the Internet, 
that they are likely to choke to death, this may stay 
with them and their families and be a fear until death, 
even though the evidence is that choking is very rare. 
There is awareness in neurology that this is an area 
which causes stress and distress to professionals [14] 
and there is a need for training in communication and 
breaking bad news [15].
People with progressive neurological disease face 
increasing disability and increasing issues. Often this 
includes difficulties in communication, due to dysar-
thria or dysphasia, or cognitive change. Thus planning 
ahead is particularly important and advance care 
planning (ACP), when the person expresses their 
wishes while they are able to do so and these are 
then known when they lose capacity to express their 
views, due to communication or cognitive change, 
is very important. However patients, families and 
professionals all find ACP difficult, although there is 
evidence that patients with MS do want to discuss 
the future [16] and wish their views to be adhered to 
[17]. Careful and sensitive discussion with patients 
and families should allow the setting of clear goals 
of care and therapy, including ACP.
Symptom management
The careful assessment of all symptoms and issu-
es — physical, psychological, social and spiritual — is 
the cornerstone of palliative care. There is a need for 
careful assessment of symptoms, in relation to the 
specific disease and its progression. Knowledge of 
the possible changes in the disease progression is 
important and palliative care providers may need to 
work collaboratively with neurology and rehabilitation 
services to maximise the best care for patients.
For instance breathlessness, and in particular or-
thopnoea and poor sleep, in ALS may be the evidence 
of respiratory muscle weakness and respiratory in-
sufficiency. Consideration of non-invasive ventilation 
is necessary, in conjunction with other symptom 
management, as NIV may relieve symptoms, improve 
quality of life and extend life by many months [18]. The 
discussion is complex, as the disease will continue to 
progress, with increasing disability.  There is also the 
risk of increasing dependence on NIV, as respiratory 
function deteriorates, and a patient may start using 
the NIV in the day, and for some the use becomes 
nearly continuous [19] and some may consider tra-
cheostomy ventilation. It is possible for patients to 
ask for ventilatory support to be stopped, and usually 
this lead to death within a short time, usually within 
hours. This is ethically acceptable, and in many legi-
slations there are no legal restrictions, but this can be 
a challenge for all concerned, as medication may be 
needed before withdrawal, to ensure that there is 
no distress. Studies have shown that in the UK that 
palliative medicine consultants find the process of 
withdrawal of NIV challenging ethically, emotionally 
and practically [20]. Careful discussion with patient, 
family and the whole multidisciplinary team is essen-
tial and there are now guidelines available, stressing 
the need for discussion, planning and support of all 
involved [21].
Pain is an important symptom to manage, and in 
neurological disease the careful assessment of the 
cause is essential. For instance pain may be related to 
the disease process itself, such as spasm and cramp 
in spastic limbs, related to immobility, such as skin 
pressure pain in ALS, or be an incidental pain due to 
immobility or unrelated, such as arthritic pain.  It is 
a common symptom present in 62% in PD [22], 76% 
in ALS [23], and 82% in MS [24].  Careful assessment 
and treatment is necessary, and careful titration of 
analgesia may be required for pain when other tre-
atable causes have been found. This may be more 
complex than in the management of pain in cancer 
and as neuropathic and central pain may be present, 
for instance in MS and stroke, and specialised mana-
gement may be necessary.   Opioids can be helpful, 
particularly in skin pressure pain [25].
Swallowing problems are common in many pa-
tients, due to problems of chewing, moving food in 
the mouth, or  swallowing, or with issues of poten-
tial aspiration due to reduced control of the airway. 
Careful assessment is essential and the involvement 
of speech and language therapy is important in the 
assessment. Careful feeding, of foods of the correct 
consistency, is helpful and many patients can continue 
oral feeding if there is good hand feeding by expe-
rienced carers [26]. However the use of a gastrostomy, 
often a percutaneous endoscopic gastrostomy, may 
need to be considered. This is not without risk and the 
benefits and risks may need to be balanced carefully. 
As swallowing deteriorates there is the risk of aspi-
ration pneumonia and oral feeding may need to be 
assessed for risk.  However, often patients may wish 
to continue to taste and enjoy food, at risk.
Communication is a basic need for all people but 
in neurological disease it may become difficult due to 
dysphasia, dysarthria, dementia and cognitive change 
or weakened respiratory effort. Speech and language 
therapy assessment is essential, and the use of ap-
propriate aids important — usually a mix of low tech 
aids, such as a spelling board or pad and paper, with 
high tech aids, such as computer based systems or eye 
gaze control if other movement has been lost [26]. 
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Consideration of the cognitive ability of the patient 
is essential, as this may reduce the effectiveness of 
the use of the communication aid. There is also the 
need to enable patients to continue communication 
by social media or other Internet systems.
There may be particular psychological issues to 
be considered in progressive neurological disease, as 
there are often fears of the disease, the possible de-
terioration and the process of dying [27]. These may 
be highlighted because of the information given to 
patients, such as the myths of choking to death in ALS, 
or from experience of seeing other family members 
deteriorate and die from the same disease, such as in 
Huntington’s disease or increasingly seen in familial 
ALS. It is important to be aware of these issues and 
listen carefully to patients and families.
Social issues are often profound, as patients and 
families face continual loss as the disease progresses, 
for instance a patient with ALS may lose ability to walk, 
to move, swallow, speak, breath unaided and even 
cognition.  These issues will impact not only on the 
patient but also the family, and other carers, including 
professionals. There is a need for proactive assessment 
and discussion, and enabling patients and families to 
express their fears and distress [27].
Spiritual issues — regarding the meaning of life, 
the existential issues and, on occasions, religious issues 
— are often very important as one faces a progres-
sive disease and deterioration [28]. As patients face 
deterioration, with possible cognitive change or loss, 
they may experience profound concerns — feelings of 
hopelessness, dependency and altered sense of worth 
and isolation — as well as fears of the future — of 
their physical or mental state or dying and death itself 
[27]. All involved in care need to be open to hear these 
issues and allow discussion.
Carer support
Family members and carers for someone with 
a progressive neurological disease face similar issues 
to the person — fears of the future, coping with co-
gnitive change and dementia, coping with increased 
communication problems, and living with the incre-
ased pressure of caring for a progressively disabled 
person. The stresses on carers may be profound and 
they will need their own support and opportunity 
to discuss their concerns and fears [27]. This burden 
may increase as the person deteriorates and there is 
the need to ensure that they have the opportunity for 
themselves and also the opportunity to be a family 
member with their loved one, rather than a carer 
with increased burden. As the end of life approaches 
extra support is necessary to allow the family to be 
able to be with the person as family, rather than as 
extended carer.
Families will also need support at the time of the 
death and in bereavement. They may have many 
mixed emotions — relief that the burden of caring 
has been lifted but also feeling guilty that they have 
these emotions when their loved one has died. Be-
reavement support and counselling may be helpful, 
although many families will show resilience and may 
just need support and explanation of their feelings 
and emotions.
Professionals will also have their own needs in 
coping with the progressive loss faced by patients and 
family carers.  Professionals may feel impotent and 
distressed by the continual losses faced by patients 
and without support depression, stress or burnout 
may occur. This is often minimised but support, in 
the form of counselling, supervision and training, is 
helpful in reducing the risks of stress and burnout [29].
End of life care
The end of life phase — the last 6 to 12 months 
— should be recognised, if possible. This allows the 
focus of care to be adjusted – looking at the provision 
of comfort and the support to all involved — patient, 
family, carers, and professionals. The discussions abo-
ut the end of life may start earlier and may occur 
particularly when the patient/family asks, or when 
new treatment is planned, especially when NIV or 
gastrostomy are suggested.
Triggers that may suggest the end of life phase is 
staring have been suggested. These are:
• swallowing problems;
• recurring infection;
• marked decline in functional status;
• first episode of aspiration pneumonia;
• cognitive difficulties;
• weight loss;
• significant complex symptoms [30].
There may be certain triggers for specific diseases, 
such as cognitive change and non-responsiveness to 
treatment for PD [30]. 
These triggers have been shown to increase as 
death approaches – with the number of triggers in-
creasing nearer to death and aspiration pneumonia 
becoming increasing more frequent, particularly in 
the last 3 to 6 months of life [31]. 
The recognition of the end of life phase is im-
portant as the focus of care can be clarified and the 
palliative care approach becomes more appropriate. 
This may include discussion with patient, if possible 
and appropriate and family and should ensure that 
they all, included in the multidisciplinary team, are 
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aware of the changes expected. The management 
of symptoms may need to be reassessed and the 
provision of medication, which may be necessary 
parenterally at the end of life — analgesia, sedative 
medication and anticholinergic medication to reduce 
chest secretions — should be made available so that 
there is no delay in providing symptom management 
at home [23]. This may include consideration of the 
continuation of medication that is necessary for the 
patient — such as the medication for Parkinson’s di-
sease when stopping this could increase stiffness and 
cause distress.  Anti-Parkinsonian treatment can be 
continued by using transdermal preparations (such 
as rotigotine patches) or apomorphine infusion [32].
There are many ethical areas that may need to be 
discussed at the end of life, or if possible when un-
dertaking advance care planning. These may include:
• Cardiopulmonary resuscitation — this may be 
inappropriate for a person with advancing disease 
and discussion with the patient, if possible and 
appropriate, and the family is very helpful, so that 
all can be clear that CPR would not be attempted, 
allowing the person to die peacefully.
• The use of antibiotic therapy for aspiration 
pneumonia at the end of life is usually ineffective 
and inappropriate and the symptoms can be ma-
naged by the use of analgesic and anticholinergic 
medication, often parenterally. Earlier discussion of 
these issues allows all involved are aware of the pa-
tient and family wishes and can act appropriately. 
• The use of gastrostomy feeding at the end of life is 
often difficult. For many patients it becomes appa-
rent that the amount of feed may be reduced and 
replaced by water to continue hydration. If there is 
no gastrostomy many families may feel that artifi-
cial hydration should be started, although there is 
little evidence that this prolongs life [33].  Careful 
discussion and consideration of cultural issues is 
important, involving the multidisciplinary team.
• Some patients may wish to discuss hastened death 
— euthanasia (the deliberate use of medication 
to end life) or assisted dying / suicide (where the 
doctor will provide medication which the patient 
would take to end their life). The legality of these 
actions varies across the World and in the majority 
or countries (including Poland) euthanasia and 
assisted dying are prohibited. However, patients 
and families may still wish to discuss the issues. It 
is important that all are prepared to listen to them, 
and see if there are specific issues which lead to 
these requests — such as the fear of pain, of a 
distressing death. These issues may be addressed 
and reassurance given that symptoms will be ma-
naged and dying from a neurological disease is 
not necessarily distressing — several surveys have 
now shown that dying is usually peaceful [34, 35].
Careful discussion of psychosocial and spiritual 
issues is important — taking into account any cultural 
issues, remembering that every family has their own 
culture. There may be  a need to discuss where the 
person wants to be cared for and where they would 
wish to die —these are often separate places [36], so 
that the patient’s and family’s views can be discussed 
and agreed.
Patients and families may fear of the dying process 
and so discussion about the reality of the management 
of symptoms is important. There is now increasing 
evidence that palliative care can reduce distress at 
the end of life and this should be mentioned to all 
involved — again this is not just patients and families 
but professionals as well [34, 35].
Education
Within the EAN/EAPC Consensus paper the need 
for education was recommended — for neurologists 
on palliative care and for palliative care specialists in 
neurology [3]. Education has been shown to improve 
care and mutual understanding and collaboration. 
This collaboration may need to be with neurology, 
palliative care, primary care (family care) and rehabi-
litation services so that the best and most appropriate 
care can be provided for patients and families [13]. 
Conclusion
Palliative care is very appropriate for the support 
of people with progressive neurological disease. Ho-
wever, there may be the need for variable involvement 
over the disease progression [37]. At times there is 
the need for involvement of specialist services, but 
at other times there may be fewer needs and less 
involvement. For instance for a person with ALS the-
re may be particular needs at the time of diagnosis, 
coping with the shock of the news, at gastrostomy, 
at the initiation of NIV and at the end of life, and this 
will be over a period of 2 to 3 years for the majority of 
patients. For a person with MS there may be specific 
symptom issues at times and involvement later in the 
disease progression and this may be over a period of 
many years, with long periods when there are fewer 
specialist needs. This variable input, according to the 
patient’s needs, is often a challenge to palliative care 
and requires a more collaborative approach with other 
services, such as rehabilitation, primary care and neu-
rology [13]. However, if the most appropriate care is to 
be provided this collaboration and close relationships 
need to be developed.
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With a close collaboration, keeping the patient and 
family at the centre of care, patients and their families 
may be supported and their issues addressed until they 
are able to die peacefully in the place of their choice.
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